CompletedNCT03504475
Comparing Paroxetine Tablets With Paxil in Healthy Chinese Adults
About this title
Bioequivalence Study of Paroxetine Tablets and Paxil® Under Fasting and Fed Conditions in Chinese Healthy Volunteers
Read the official source — NCT03504475Medication studyAges 18–65ChinaAnxiety
Understand this study
Who was this study for?
Listed age limits: 18 years to 65 years.
- Listed locations
- Beijing and 1 more locationSee all locations and recruitment
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Study information
Study start dateStarted: March 29, 2018
- Recruitment status
- Completed
- Enrollment listed in the registry
- 53
- Sponsor
- Beijing Tongren Hospital
- Sponsor type
- Hospital / academic medical center
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
- Locations
- China
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT03504475
- Official title
Show the full official title
An Open-Label Randomized, Single-Dose, 2-way Crossover Bioequivalence Study of Paroxetine Hydrochloride 20 mg Tablets and Paxil® Under Fasting Conditions and Under Fed Conditions in Chinese Healthy Volunteers
Get this study by email
Recruitment & locations
CompletedBeijing
Questions about this study
Who is behind this study?
The study sponsor is Beijing Tongren Hospital, a hospital or academic medical center.
Did this study involve medication?
Yes. The study involved medication, including Paroxetine Hydrochloride Tablet 20 mg and Paxil® 20 mg.
Who was this study for?
Listed age limits: 18 years to 65 years.
